Johns Hopkins-MedImmune Scholars Program » Johns Hopkins Drug Discovery
2092
page-template,page-template-full_width,page-template-full_width-php,page,page-id-2092,page-parent,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-4.12.1,vc_responsive

Johns Hopkins-MedImmune Scholars Program

Click here for the call for proposals in the areas of respiratory, inflammation and autoimmunity diseases
Click here for the call for proposals in the areas of oncology
Click here for the call for proposals in the areas of antibody design and protein engineering (ADPE)

About the program

The Johns Hopkins-MedImmune Scholars Program is a first-of-its-kind Ph.D. training program jointly implemented by the Johns Hopkins University’s Center for Innovation in Graduate Biomedical Education and MedImmune, the global biologics research and development arm of AstraZeneca. Students in this program will be mentored by a pair of co-supervisors, one at Johns Hopkins and the other at MedImmune. In addition to the standard Johns Hopkins course curriculum and Ph.D. thesis project, students will be introduced to the process and challenges of drug discovery and development through coursework in translational research as well as lab work conducted at MedImmune under the direction of MedImmune co-supervisors. This unique approach to training will offer graduate students hands-on experience in the biomedical field and prepare them for careers in the biopharma industry, while still obtaining a traditional Ph.D. from a world-class university.

 

Program eligibility

Graduate students enrolled in Ph.D.-granting programs (entering 2016 or later) at any of the schools of the Johns Hopkins University are eligible to apply for the program as long as co-supervisors can be identified with an agreeable joint Ph.D. thesis project plan.

 

Application process

In order to minimize the upfront burden of paperwork, the application process for the Johns Hopkins-MedImmune Scholars Program is intentionally kept informal at the early phase. The key question at this phase is whether joint Ph.D. thesis plans can be developed by students and co-supervisors. Dr. Takashi Tsukamoto, Program Director, will facilitate this process by working closely with potential students and co-supervisors. Once agreeable plans are established, the process enters more formal steps including in-depth review of the applications by the Johns Hopkins MedImmune Joint Committee for final decision.

 

Course requirements

In addition to courses required by the home graduate program, Johns Hopkins-MedImmune Scholars must complete the three courses listed below on translational research. These courses are offered by Johns Hopkins Drug Discovery and are designed to cover various topics on drug discovery and development to complement the basic science courses offered by the home graduate programs.

 

 

If you are interested but undecided on whether to apply for the Johns Hopkins-MedImmune Scholars Program, it may be beneficial to start taking these courses as electives in your graduate program to avoid excessive course load in the later years.

 

Students with disabilities

The Johns Hopkins-MedImmune Scholars Program encourages students with disabilities to apply for the program. Johns Hopkins University is committed to providing reasonable and appropriate accommodations to students with disabilities. Students with documented disabilities should contact the coordinator listed on the Disability Accommodations page.

 

Learning more about the program

If you are a graduate student and interested in becoming a Johns Hopkins-MedImmune Scholar, the first step is to contact Dr. Tsukamoto, who will guide you through the process of exploring the feasibility of being selected for the program.

If you are a Johns Hopkins principal investigator affiliated with a Ph.D.-granting program and are interested in learning more about potential opportunities to work with MedImmune investigators through this program for future graduate students, Dr. Tsukamoto can serve as a point person to facilitate the communication with the MedImmune counterpart.

 

Program Director

Takashi Tsukamoto Ph.D.
Associate Professor of Neurology
Johns Hopkins Drug Discovery
Johns Hopkins University
855 N Wolfe Street, Rangos 231
Baltimore, MD 21205
ttsukamoto@jhmi.edu

lowgo_bottom